Practical Importance Use Of Modern Probiotics In Complex Treatment Of Adenoviral Conjunctivitis

Аннотация

Adenoviral conjunctivitis is an inflammatory disease of the conjunctiva that spreads at the epidemic level, the main reason for which is explained by the fact that it is rapidly spread by airborne and domestic routes and has a high degree of contagiousness. In clinical practice, viral eye pathologies develop the background of upper and lower respiratory (especially rhinitis, sinusitis, tonsillitis, bronchitis) and antibiotics are often used to treat bacterial complications in this category of patients. As a result, the balance of the immunomicrobiological environment in the intestines of some patients is disturbed [1,2,7] In this contingent of patients, eye pathologies of viral etiology persist for a long time. In modern practice, an integrated approach is used to increase the effectiveness of the prevention and treatment of adenoviral conjunctivitis. In addition, complex treatment of adenoviral conjunctivitis is required that the adequate use of antiviral and immunomodulatory drugs, as well as the inclusion new group of drugs in the treatment algorithm for increasing effectiveness and eliminate symptoms of this disease [3,5]. Probiotics stimulate the body's specific (antibody and immune system) and non-specific (skin, mucous membranes and tears) immunity by restoring the normal intestinal microflora balance, resulting in activation of cellular and humoral immune processes. The use of modern probiotics during treatment period decreased the production of cytokines in the patient's body in the same time increased of endogenous interferon’s concentration in the blood [1,3,4,6]. Even during an epidemic of adinoviral conjunctivitis, the inclusion of multi-component probiotics such as Bifolak Zincum + C + D3 in the complex treatment plan is effective and safe. KEYWORDS Adenoviral conjunctivitis, immunomodulator, Bifolak Zincum + C + D3, endogenous interferon, multicomponent probiotics, complex therapy. The US A Journals Volume 03 Issue 01-2021 210 The American Journal of Medical Sciences and Pharmaceutical Research IMPACT FACTOR (ISSN – 2689-1026) 2021: 5. 64 Published: January 31, 2021 | Pages: 210-215 Doi: https://doi.org/10.37547/TAJMSPR/Volume03Issue01-32 O CLC - 1121105510